Department of Physiology and Pathophysiology, School of basic medical science, Cheeloo College of Medicine, Shandong University, Jinan, China.
The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Qilu Hospital, Shandong University, Jinan, China.
Cell Death Dis. 2021 Oct 30;12(11):1034. doi: 10.1038/s41419-021-04325-z.
Chemotherapy-induced intestinal mucositis (CIM) is a common adverse reaction to antineoplastic treatment with few appropriate, specific interventions. We aimed to identify the role of the G protein coupled estrogen receptor (GPER) in CIM and its mechanism. Adult male C57BL/6 mice were intraperitoneally injected with 5-fluorouracil to establish the CIM model. The selective GPER agonist G-1 significantly inhibited weight loss and histological damage in CIM mice and restored mucosal barrier dysfunction, including improving the expression of ZO-1, increasing the number of goblet cells, and decreasing mucosal permeability. Moreover, G-1 treatment did not alter the antitumor effect of 5-fluorouracil. In the CIM model, G-1 therapy reduced the expression of proapoptotic protein and cyclin D1 and cyclin B1, reversed the changes in the number of TUNEL cells, Ki67 and bromodeoxyuridine cells in crypts. The selective GPER antagonist G15 eliminated all of the above effects caused by G-1 on CIM, and application of G15 alone increased the severity of CIM. GPER was predominantly expressed in ileal crypts, and G-1 inhibited the DNA damage induced by 5-fluorouracil in vivo and vitro, as confirmed by the decrease in the number of γH2AX cells in the crypts and the comet assay results. Referring to the data from GEO dataset we verified GPER activation restored ERK1/2 activity in CIM and 5-fluorouracil-treated IEC-6 cells. Once the effects of G-1 on ERK1/2 activity were abolished with the ERK1/2 inhibitor PD0325901, the effects of G-1 on DNA damage both in vivo and in vitro were eliminated. Correspondingly, all of the manifestations of G-1 protection against CIM were inhibited by PD0325901, such as body weight and histological changes, the mucosal barrier, the apoptosis and proliferation of crypt cells. In conclusion, GPER activation prevents CIM by inhibiting crypt cell DNA damage in an ERK1/2-dependent manner, suggesting GPER might be a target preventing CIM.
化疗诱导的肠道黏膜炎(CIM)是一种常见的抗肿瘤治疗不良反应,目前仅有少数适当的、特异性的干预措施。本研究旨在确定 G 蛋白偶联雌激素受体(GPER)在 CIM 中的作用及其机制。雄性 C57BL/6 小鼠腹腔注射氟尿嘧啶建立 CIM 模型。选择性 GPER 激动剂 G-1 可显著抑制 CIM 小鼠的体重减轻和组织学损伤,并恢复黏膜屏障功能,包括改善 ZO-1 的表达、增加杯状细胞数量和降低黏膜通透性。此外,G-1 处理并不改变氟尿嘧啶的抗肿瘤作用。在 CIM 模型中,G-1 治疗可降低促凋亡蛋白和细胞周期蛋白 D1、B1 的表达,逆转隐窝中 TUNEL 细胞、Ki67 和溴脱氧尿苷细胞数量的变化。选择性 GPER 拮抗剂 G15 消除了 G-1 对 CIM 的所有上述作用,而 G15 单独应用则加重了 CIM 的严重程度。GPER 主要表达于回肠隐窝,G-1 抑制氟尿嘧啶在体内和体外诱导的 DNA 损伤,这可通过隐窝中γH2AX 细胞数量的减少和彗星试验结果得到证实。参考 GEO 数据集的数据,我们验证了 GPER 激活可恢复 CIM 和氟尿嘧啶处理的 IEC-6 细胞中 ERK1/2 的活性。用 ERK1/2 抑制剂 PD0325901 消除 G-1 对 ERK1/2 活性的影响后,G-1 对体内和体外 DNA 损伤的作用也被消除。相应地,PD0325901 抑制了 G-1 对 CIM 的所有保护作用,如体重和组织学变化、黏膜屏障、隐窝细胞的凋亡和增殖。总之,GPER 激活通过 ERK1/2 依赖性抑制隐窝细胞 DNA 损伤来预防 CIM,提示 GPER 可能是预防 CIM 的一个靶点。